GeneDx

Forecast & Rating9 analysts currently cover GeneDx, with about 88.9% giving a positive rating — meaning they expect the stock to rise. The average price target is $92.38, about 26.4% upside from the current price of $73.08. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 45.7% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study GeneDx closely still see room for the stock to rise. Data as of Sep 30, 2026; for reference only and not investment advice.